American Express (AXP) Offering Possible 19.05% Return Over the Next 6 Calendar Days

American Express's most recent trend suggests a bullish bias. One trading opportunity on American Express is a Bull Put Spread using a strike $120.00 short put and a strike $115.00 long put offers a potential 19.05% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $120.00 by expiration. The full premium credit of $0.80 would be kept by the premium seller. The risk of $4.20 would be incurred if the stock dropped below the $115.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for American Express is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for American Express is bullish.

The RSI indicator is at 56.44 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for American Express

Day One Launch of Collection Sites COVID-19 Testing Site at Town of East Hampton Model of Success
Thu, 07 Jan 2021 21:54:00 +0000
Collection Sites testing centre at the Town of East Hampton’s Town Hall Campus provides meaningful testing services on opening day; represents model of success for proper COVID-19 testing access. Meanginful COVID-19 Testing Services Provide On Opening Day at East Hampton Figure 1: Images of Line-ups at East Hampton’s Town Hall Campus Meanginful COVID-19 Testing Services Provide On Opening Day at East Hampton Figure 2: Images of Line-ups at East Hampton’s Town Hall CampusTORONTO, Jan. 07, 2021 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve”) (formerly “QuestCap Inc.”) (NEO:MEDV; OTC:COPRF; FRA:34C1) is pleased to announce the opening of a new collection site at the Town of East Hampton’s Town Hall Campus was highly successful. This site saw substantial demand for important COVID-19 testing services on the first day of operation and will serve as a replicable model for future site launches across the United States. Meanginful COVID-19 Testing Services Provide On Opening Day at East Hamptonhttps://www.globenewswire.com/NewsRoom/AttachmentNg/306433b0-7251-461c-a8bd-c7d7c8f1bee2https://www.globenewswire.com/NewsRoom/AttachmentNg/e864cf68-7a48-42f8-8a51-458f848f59eb Figure 1 & 2: Images of Line-ups at East Hampton’s Town Hall Campus With individual sites currently achieving strong sales with 7-day rolling average of 95 tests per day and average test price exceeding US$95 per test, this one site is expected to add to Medivolve’s top-line revenue immediately.As a reminder, effective yesterday the Company commence trading of its common shares under its new name “Medivolve Inc.” and new ticker “MEDV” on the NEO.About the East Hampton Collection Site Opening Local media has also recognized the value of Collection Sites COVID-19 testing centres, covering the launch of the site with an article (view article). Please note this site be a standard walk-up testing site. With a strong location and a town population of over 20,000, this testing site is expected to generate strong sales over the period of operation.“By partnering with the local municipality, we were able to successfully launch a Collection Site in a short time period and see strong sales on the first day,” says Mr. Tim Shelburn, President of Collection Sites. “We are excited see the success of this approach and will strive to replicate it. We commend the municipality for their forward thinking approach to COVID-19 testing for their constituents.”The pop-up labs will be managed by Las Vegas based company Collection Sites, LLC and powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. Appointments and payments will be handled through an online portal www.testbeforeyougo.com.The key to flattening the curve is to increase testing.The testing centers will offer convenient access to rapid antibody and antigen (pending availability) tests – which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR.  All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.For more information about the pop-up lab, the available sites and services visit www.testbeforeyougo.com.About Medivolve Inc.Medivolve Inc. (NEO:MEDV; OTC:COPRF; FRA:34C1)  seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.Medivolve’s primary focus is the sale of COVID-19 IgG/IgM antibody tests authorized by FDA under an EUA for use by authorized laboratories. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal  www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.For additional information, please contact:Doug Sommerville, CEO Doug.Sommerville@questcapinc.com +1 416-301-5418For investing inquiries please contact: Evan Veryard Evan.veryard@questcapinc.comFor US media enquiries please contact: Veronica Welch veronica@vewprmedia.com +1-508-643-8000Cautionary Note Regarding Forward-looking InformationThis press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the agreement among Collection Sites LLC and the Town of East Hampton; the proposed roll-out of testing sites; projected timelines for testing results; projected revenues from the testing; the pursuit by Medivolve of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Top Stock Reports for UnitedHealth, Netflix & Caterpillar
Thu, 07 Jan 2021 17:05:05 +0000
Top Stock Reports for UnitedHealth, Netflix & Caterpillar

4 Stocks to Gain Traction From Fintech Evolution in 2021
Thu, 07 Jan 2021 14:50:02 +0000
Fintech applications add a new dimension to customer services and are poised to grow further in 2021. Synchrony Financial (SYF), Usio (USIO), American Express (AXP) and PayPal (PYPL) are stocks to watch out for.

Billionaire Andreas Halvorsen’s Top 10 Stock Picks
Wed, 06 Jan 2021 15:53:00 +0000
In this article, we presented billionaire Andreas Halvorsen’s top 10 stock picks. Click to skip ahead and see Billionaire Andreas Halvorsen’s Top 5 Stock Picks. The billionaire Andreas Halvorsen’s Viking Global Investors LP has beaten the broader market index in 2020 by returning 25% after management and performance fees. This is not the first time […]

Collection Sites Launches COVID-19 Testing Site at Town of East Hampton’s Town Hall Campus; Medivolve Inc. Name Change Becomes Effective Today
Wed, 06 Jan 2021 12:30:00 +0000
Through a partnership with the Town of East Hampton, Collection Sites opens testing centre at the town’s Town Hall Campus, completing expansion into New York.TORONTO, Jan. 06, 2021 (GLOBE NEWSWIRE) — Medivolve Inc. (“Medivolve”) (formerly “QuestCap Inc.”) (NEO:MEDV; OTC:COPRF; FRA:34C1) is pleased to announce the opening of a new collection site at the Town of East Hampton’s Town Hall Campus. This site will provide COVID-19 testing services for an initial term of 6-months. With individual sites currently achieving strong sales with 7-day rolling average of 96 tests per day and average test price exceeding US$95 per test, this one site can add substantively to Medivolve’s top-line revenue. In addition, the Company announces that trading of its common shares under its new name “Medivolve Inc.” and new ticker “MEDV” on the NEO is expected to commence on January 6, 2021, one day earlier than as previously stated in a press release dated December 29, 2020.About the East Hampton Collection Site Opening Local media has also recognized the value of Collection Sites COVID-19 testing centres, covering the launch of the site with an article (view article). Please note this site be a standard walk-up testing site. With a strong location and a town population of over 20,000, this testing site is expected to generate strong sales over the period of operation.“After working closely with the Town of East Hampton, we are happy to officially launch the collection site and provide COVID-19 testing services to local residents,” says Mr. Tim Shelburn, President of Collection Sites. “As individuals return from holiday, we expect a strong demand for testing, especially as local media provide continued recognition for our testing centres.”The pop-up labs will be managed by Las Vegas based company Collection Sites, LLC and powered by Alcala Testing and Analysis Services, a CLIA-licensed laboratory based in San Diego, California. Appointments and payments will be handled through an online portal www.testbeforeyougo.com.The key to flattening the curve is to increase testing.The testing centers will offer convenient access to rapid antibody and antigen (pending availability) tests – which take 8-10 minutes to administer and provide results within 24 hours. The sites also offer regular RT-PCR. All tests can be administered with insurance coverage options. The tests results can be communicated via text or email and can be accompanied with a certificate of good health via a HIPAA-compliant smartphone application.For more information about the pop-up lab, the available sites and services visit www.testbeforeyougo.com.About Medivolve Inc.Medivolve Inc. (NEO:MEDV; OTC:COPRF; FRA:34C1) seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.Medivolve’s primary focus is the sale of COVID-19 IgG/IgM antibody tests authorized by FDA under an EUA for use by authorized laboratories. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.For additional information, please contact:Doug Sommerville, CEO Doug.Sommerville@questcapinc.com +1 416-301-5418For investing inquiries please contact: Evan Veryard Evan.veryard@questcapinc.comFor US media enquires please contact: Veronica Welch veronica@vewprmedia.com +1-508-643-8000Cautionary Note Regarding Forward-looking InformationThis press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the agreement among Collection Sites LLC and the Town of East Hampton; the proposed roll-out of testing sites; projected timelines for testing results; projected revenues from the testing; the pursuit by Medivolve of investment opportunities; and the merits or potential returns of any such investments. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”,, “expects”, or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.